COL4A3 and kidney disorder: Compared with vehicle-treated F1-Col4a3−/− mice, both ACEi and anti-miR-21 therapies were effective in delaying the progression of kidney disease, which manifested as slower increases in BUN (Figure 3c, Table S6).